Browse ZMYND10

Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite Note=Localizes to sites proximal to the axoneme.
Domain PF01753 MYND finger
Function

Required for motile ciliary function. Probably involved in axonemal assembly of inner and outer dynein arms (IDA and ODA, respectively) for proper axoneme building for cilia motility. May act by indirectly regulating transcription of dynein proteins.

> Gene Ontology
 
Biological Process GO:0000226 microtubule cytoskeleton organization
GO:0001578 microtubule bundle formation
GO:0010927 cellular component assembly involved in morphogenesis
GO:0030031 cell projection assembly
GO:0035082 axoneme assembly
GO:0036158 outer dynein arm assembly
GO:0036159 inner dynein arm assembly
GO:0042384 cilium assembly
GO:0044458 motile cilium assembly
GO:0044782 cilium organization
GO:0060271 cilium morphogenesis
GO:0070286 axonemal dynein complex assembly
Molecular Function -
Cellular Component GO:0005813 centrosome
GO:0034451 centriolar satellite
GO:0044450 microtubule organizing center part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZMYND10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZMYND10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZMYND10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3530.163
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4370.333
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2890.45
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9330.0249
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0890.39
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7360.634
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5520.129
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.6450.313
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4750.483
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1990.893
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.9960.617
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1780.39
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ZMYND10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZMYND10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZMYND10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZMYND10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZMYND10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZMYND10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZMYND10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZMYND10
Namezinc finger, MYND-type containing 10
Aliases BLU; CILD22; FLU; protein BLu; Zinc finger MYND domain-containing protein 10
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZMYND10 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.